Notas del episodio
Discussing the FDAs recent reversal on compounding Terzepitide while they re-evaluate the shortage situation. This and more on today's episode.
Palabras clave
shortagecompounded medicationsbranded medicationsTerzepitidemanufacturingFDAstop manufactureconsequencesreversal